128 related articles for article (PubMed ID: 32664151)
1. XPC exon15 Lys939Gln variant increase susceptibility to prostate adenocarcinoma: Evidence based on 4306 patients and 4779 controls.
Qin F; Gao SL; Xu K; Su QX; Zhang Z; Shi L; Zhu LJ; Zhang LF; Zuo L
Medicine (Baltimore); 2020 Jul; 99(28):e21160. PubMed ID: 32664151
[TBL] [Abstract][Full Text] [Related]
2. Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer.
Yan Y; Xu J; Xu B; Wen Q; Zhou J; Zhang L; Zuo L; Lv G; Shi Y
J Clin Lab Anal; 2020 Sep; 34(9):e23403. PubMed ID: 32488882
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of XPC Ala499Val and Lys939Gln polymorphisms to risks of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Zhou RM; Li Y; Wang N; Zhang XJ; Dong XJ; Guo W
Ai Zheng; 2006 Sep; 25(9):1113-9. PubMed ID: 16965652
[TBL] [Abstract][Full Text] [Related]
4. Association of DNA repair gene XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case-control study in a South Indian population.
Lakkireddy S; Aula S; Kapley A; Gundeti S; Kutala VK; Jamil K
J Gene Med; 2021 Jul; 23(7):e3339. PubMed ID: 33829606
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in XPC gene and risk for prostate cancer.
Said R; Bougatef K; Setti Boubaker N; Jenni R; Derouiche A; Chebil M; Ouerhani S
Mol Biol Rep; 2019 Feb; 46(1):1117-1125. PubMed ID: 30552616
[TBL] [Abstract][Full Text] [Related]
6. XPC Lys939Gln polymorphism, smoking and risk of sporadic colorectal cancer among Malaysians.
Ahmad Aizat AA; Siti Nurfatimah MS; Aminudin MM; Ankathil R
World J Gastroenterol; 2013 Jun; 19(23):3623-8. PubMed ID: 23801864
[TBL] [Abstract][Full Text] [Related]
7. XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis.
Peng Q; Lao X; Tang W; Chen Z; Li R; Qin X; Li S
Diagn Pathol; 2014 Jun; 9():120. PubMed ID: 24947936
[TBL] [Abstract][Full Text] [Related]
8. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.
Zhang Y; Wang X; Zhang W; Gong S
Tumour Biol; 2013 Apr; 34(2):973-82. PubMed ID: 23269608
[TBL] [Abstract][Full Text] [Related]
9. Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Yang X; Liu D; Wu H; Kang H; Pang H; Huang D; Sha X; Wang E; Wang Z; Wei M
Cancer Sci; 2012 Jul; 103(7):1207-14. PubMed ID: 22519360
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China.
Dong Z; Guo W; Zhou R; Wan L; Li Y; Wang N; Kuang G; Wang S
J Clin Gastroenterol; 2008 Sep; 42(8):910-5. PubMed ID: 18645534
[TBL] [Abstract][Full Text] [Related]
11. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis.
Zhu ML; Hua RX; Zheng L
Tumour Biol; 2014 Apr; 35(4):2931-9. PubMed ID: 24375193
[TBL] [Abstract][Full Text] [Related]
12. Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma--a case-control study in China.
Jiao X; Ren J; Chen H; Ma J; Rao S; Huang K; Wu S; Fu J; Su X; Luo C; Shi J; Broelsch CE
Carcinogenesis; 2011 Apr; 32(4):496-501. PubMed ID: 21113018
[TBL] [Abstract][Full Text] [Related]
13. XPC Lys939Gln and Ala499Val polymorphisms in colorectal cancer susceptibility: a meta-analysis of case-control studies.
Liu C; Yin Q; Ying M; Lin J; Li L; Jiao G; Wang M; Wang Y
Mol Biol Rep; 2014 Feb; 41(2):1171-8. PubMed ID: 24385304
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between XPC Lys939Gln polymorphism and prostate cancer risk: an updated meta-analysis based on 3039 cases and 3253 controls.
Wu H; Lv Z; Wang X; Zhang L; Mo N
Int J Clin Exp Med; 2015; 8(10):17959-67. PubMed ID: 26770390
[TBL] [Abstract][Full Text] [Related]
15. Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis.
Asadian F; Niktabar SM; Ghelmani Y; Kargar S; Akbarian E; Emarati SA; Sadeghizadeh-Yazdi J; Neamatzadeh H
Acta Medica (Hradec Kralove); 2020; 63(3):101-112. PubMed ID: 33002396
[TBL] [Abstract][Full Text] [Related]
16. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis.
He J; Shi TY; Zhu ML; Wang MY; Li QX; Wei QY
Int J Cancer; 2013 Oct; 133(8):1765-75. PubMed ID: 23400628
[TBL] [Abstract][Full Text] [Related]
17. Association of XPC Gene Polymorphisms with Prostate Cancer Risk.
Kahnamouei SA; Narouie B; Sotoudeh M; Mollakouchekian MJ; Simforoosh N; Ziaee SA; Samzadeh M; Afshari M; Jamaldini SH; Imeni M; Hasanzad M
Clin Lab; 2016; 62(6):1009-15. PubMed ID: 27468562
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk.
Zhou L; Lu Y; Yang G; Wu J
Tumour Biol; 2014 Feb; 35(2):1427-32. PubMed ID: 24277375
[TBL] [Abstract][Full Text] [Related]
19. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
20. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.
Dou K; Xu Q; Han X
Diagn Pathol; 2013 Jul; 8():112. PubMed ID: 23819639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
